Search

You searched for "patient"

1099 results found

Benign prostatic hyperplasia: what are the benefits and harms of various surgical management options?

9 March 2020 | | URO - Functional / Reconstructive Urology, URO - Infection, URO - Neurourology, URO - Technology
Benign prostatic hyperplasia (BPH) is characterised by stromal and epithelial prostatic cell hyperplasia. The enlarged prostate may be associated with voiding and storage lower urinary tract symptoms (LUTS). These have been predominantly attributed to bladder outlet obstruction (BOO), assumed to...

ICS (International Continence Society) 2024

23 October 2024 -25 October 2024
Each year, the International Continence Society hosts its annual meeting bringing together healthcare professionals interested in treating incontinence patients. Attendees can benefit from the latest research, professional development and networking opportunities. It provides a platform to exchange ideas and share best practices. Leading experts in the field also present workshops and state of the art sessions.

ICS -EUS (International Continence Society and the Emirates Urological Society) Annual Meeting 2025

17 September 2025 -20 September 2025
A special joint Annual Meeting of the International Continence Society and the Emirates Urological Society, taking place in vibrant Abu Dhabi in 2025. Inviting healthcare professionals from around the world interested in treating incontinence patients. Attendees can benefit from the...

Management of RHC in prostate cancer with selective embolisation and hyperbaric oxygen therapy

4 July 2024 | | URO - Urologic Oncology
Prostate cancer is one of the most prevalent malignancies affecting men worldwide. Radiotherapy is a common treatment modality for localised and locally advanced prostate cancer. While radiotherapy can be effective, it may lead to complications such as radiation-induced haemorrhagic cystitis...

Recent advances in the management of castration resistant prostate cancer

1 November 2017 | | URO - Urologic Oncology
Castrate resistant prostate cancer (CRPC) is defined by disease progression despite androgen-deprivation therapy lowering testosterone to castrate levels. It may present as a rise in serum levels of prostate specific antigen (PSA), progression of pre-existing disease, or the appearance of...

History of prostate biopsy – part 2

1 September 2018 | | URO - Basic Science Research, URO - Urologic Oncology, URO - Technology
For Part 1 of this topic is available here. The major limitations of the transrectal ultrasound (TRUS) guided prostate biopsy (PBx) protocols are the risk of profound sepsis and the risk of persistently significant false negative rates, related to the...

Prostate cancer nurse specialist shortage: a view from the coal face

5 November 2019 | | URO - Urologic Oncology
Prostate Cancer UK recently reported that there is an impending crisis for men with prostate cancer, simply because the number of nurse specialists available is insufficient for their needs [1]. Background As has been widely reported, the incidence of prostate...

Focal therapy trials

6 November 2020 | | URO - Urologic Oncology
Men with localised prostate cancer have traditionally required whole gland treatment involving radical prostatectomy or radical radiation treatment, independent of disease location and size. Increasing evidence supports the use of active treatment only in those men diagnosed with prostate cancer...

NICE has recently moved the IRE guidelines from ‘Research Only’ to ‘Special Arrangements’

12 September 2023 | Company Profiles, Contracts & Distributors, Research & Development
This recent update provides increased access to the AngioDynamics NanoKnife IRE ablation...

Trials offering cytoreductive surgery for men with de novo synchronous metastatic prostate cancer

8 November 2021 | | URO - Basic Science Research, URO - Urologic Oncology
Life expectancy in men diagnosed with de novo synchronous metastatic hormone-sensitive prostate cancer (mHSPC) has risen to a median of 4.8 years with upfront systemic agents (such as docetaxel) in addition to standard androgen deprivation therapy (ADT) [1-3]. Within this...

The medical management of LUTS/BPH – an update

1 July 2018 | | URO - Functional / Reconstructive Urology
For many years it has been recognised by both medical professionals and the general public that the development of lower urinary tract symptoms (LUTS) is highly prevalent and is predominantly age-dependent. Medical professionals understand that in men this is often,...

A greener urology

13 August 2020 | | URO - Technology
Healthcare in England is responsible for 4-5% of the country’s carbon footprint which is defined as the amount of greenhouse gasses, primarily carbon dioxide, released into the atmosphere by a particular activity. The six greenhouse gasses which vary in their...